What is the current consensus among gynecologists on treating stubborn recurrent yeast infections when azole medications stop working after a few days
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What is the current consensus among gynecologists on treating stubborn recurrent yeast infections when azole medications stop working after a few days
3 real searches · 1 real-search pass
2025 guidelines recurrent vulvovaginal candidiasis azole resistant Candida culture susceptibility gynecology CDC ACOG IDSAGoogle ↗
OBSERVED
CDC vulvovaginal candidiasis recurrent culture susceptibility non-albicans treatment boric acid 2024Google ↗
OBSERVED
ACOG recurrent vulvovaginal candidiasis practice bulletin culture speciation susceptibilityGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
2025 guidelines recurrent vulvovaginal candidiasis azole resistant Candida culture susceptibility gynecology CDC ACOG IDSA Google ↗
CDC vulvovaginal candidiasis recurrent culture susceptibility non-albicans treatment boric acid 2024 Google ↗
ACOG recurrent vulvovaginal candidiasis practice bulletin culture speciation susceptibility Google ↗
- Vulvovaginal Candidiasis · cdc.gov
- Sexually Transmitted Infections Treatment Guidelines, 2021 · cdc.gov
- ACOG PRACTICE BULLETIN · aruplab.com
- IDSA 2016 Clinical Practice Guideline Update for the Management of Candidiasis · idsociety.org
- Assessment and Treatment of Vaginitis : Obstetrics & Gynecology · doi.org
- Treatment of Candidiasis | Candidiasis · cdc.gov
- Assessment and Treatment of Vaginitis · pubmed.ncbi.nlm.nih.gov
- label · accessdata.fda.gov
- These highlights do not include all the information needed to use VIVJOA™ safely and effectively. See full prescribing information for VIVJOA™. VIVJOA™ (oteseconazole) capsules, for oral use Initial U.S. Approval: 2022 · dailymed.nlm.nih.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2025 guidelines recurrent vulvovaginal candidiasis azole resistant Candida culture susceptibility gynecology CDC ACOG IDSA OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
CDC vulvovaginal candidiasis recurrent culture susceptibility non-albicans treatment boric acid 2024 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
ACOG recurrent vulvovaginal candidiasis practice bulletin culture speciation susceptibility OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |